Dicerna Pharma (DRNA) Tops Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 9, 2021 7:30 AM ESTReported Positive Top-Line Data From Pivotal PHYOX2 Clinical Trial of Nedosiran Investigational GalXC RNAi Therapy for Treatment of Primary Hyperoxaluria (PH)
Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD)
Company Plans to Unveil First GalXC-Plus Extrahepatic Target in Early 2022
Cash Runway Extends Into 2025
Company to Host Conference Call Today at 8:30 a.m. ET
LEXINGTON, Mass.--(BUSINESS... More
